Skip to main content

Farrow Jeffrey S's Form 4 filing

Tarsus Pharmaceuticals, Inc. (TARS) · filed Jun 20, 2024

Accession no.
0001819790-24-000089
Filed
Jun 20, 2024
Trade date
Jun 17-18, 2024
Filing delay
3 days
Rule 10b5-1 plan
Not checked

This filing lists 2 non-derivative transactions and 1 derivative transaction. Open-market sales total $286.9K. It was filed 3 days after the trade.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Farrow Jeffrey SCIK 0001405253Officer (See Remarks)

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Jun 17, 2024Common StockMOption exerciseAcquired+27,881–F1–28,581Direct
Jun 18, 2024Common StockSSaleDisposed−10,445$27.47−$286,924.1518,136Direct

Derivative securities (Table II)

Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.

Derivative transactions
Trade dateSecurityTransactionUnderlying sharesUnit priceValueHeld afterOwnershipFlags
Jun 17, 2024Common StockMOption exerciseDisposed−27,881$0.00$083,644Direct

Footnotes and remarks

Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.

F1

The shares were issued pursuant to settlement of vested Restricted Stock Units ("RSUs").

Referenced by the price of 1 transaction in Table I.

Remarks

Chief Financial Officer and Chief Strategy Officer

Read the full filing on SEC EDGAR (opens in a new tab)